Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis

PURPOSE: The KEYNOTE‐062 trial demonstrated the efficacy and safety of pembrolizumab for advanced gastric cancer (GC). The current study evaluated the cost‐effectiveness of pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced GC from the perspective of the United...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Yitian, Lin, Yan, Li, Dan, Liu, Jiyong, Liu, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557869/
https://www.ncbi.nlm.nih.gov/pubmed/37706223
http://dx.doi.org/10.1002/cam4.6389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557869/
https://www.ncbi.nlm.nih.gov/pubmed/37706223
http://dx.doi.org/10.1002/cam4.6389

Ejemplares similares